NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma (FOXAGAST)

Phase II Study of NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma

This is a non-randomized pauci-centre, open-label phase II study. The treatment will consist in a chemotherapy by FOLFOX and nab-paclitaxel following modalities determined in the Brown University Phase I study.

In neoadjuvant setting : 3 months of treatment

Main criteria of Withdraw of the treatment: in case of tumor progression, non acceptable toxicity, or patient decision.

Post-operative treatment (for 6 additional cycles) is recommended, but will depend on the result of the neo-adjuvant treatment and the ability of patients to receive adjuvant chemotherapy based on tolerance of neo-adjuvant treatment and general post-operative condition (i.e. adjuvant treatment if no progression during neo-adjuvant chemotherapy, less than 80% of residual viable tumor compared to initial tumor volume, acceptable tolerance and post-operative PS 0 - 2). Adjuvant treatment must be initiated within 8 weeks post-operatively.

Study Overview

• Status: Unknown
• Conditions: Cancer of Stomach
• Intervention / Treatment: Drug: nab-paclitaxel; Drug: FOLFOX

Detailed Description

This is a non-randomized pauci-centre, open-label phase II study. The treatment will consist in a chemotherapy by FOLFOX and nab-paclitaxel following modalities determined in the Brown University Phase I study.

In neoadjuvant setting : 3 months of treatment

Main criteria of Withdraw of the treatment: in case of tumor progression, non acceptable toxicity, or patient decision.

• Study Type: Interventional
• Enrollment (Anticipated): 55
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Christophe LOUVET; Phone Number: 33 1 56 61 60 35; Email: christophe.louvet@imm.fr

Study Locations

• France
  • Besancon, France, 25030
    • Recruiting
    • Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
    • Contact: Phone Number: 33-3-8166-8393
    • Principal Investigator: Stéphano KIM
  • Creteil, France, 94000
    • Recruiting
    • Centre Hospitalier Universitaire Henri Mondor
    • Contact: Phone Number: 33-1-4981-2579
  • Lyon, France
    • Recruiting
    • Centre Leon Berard
  • Lyon, France
    • Recruiting
    • Hopital Prive Jean Mermoz
    • Principal Investigator: Gérard LLEDO
  • Paris, France
    • Recruiting
    • Hopital Saint Antoine
    • Principal Investigator: Thierry Andre
  • Paris, France
    • Recruiting
    • Institut Mutualiste Montsouris
    • Contact: Christophe, PhD
    • Principal Investigator: Christophe LOUVET, PhD
  • Paris, France, 75651
    • Recruiting
    • CHU Pitié-Salpêtrière
    • Principal Investigator: Jean-Baptiste Bachet
    • Contact: Phone Number: 33-1-42-16-00-00

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed and dated informed consent, and willing and able to comply with protocol requirements,
• Histologically or cytologically proven adenocarcinoma of the low oesophagus or of the stomach, (from 1/3 inferior of the oesophagus to pylorus)
• HER2 negative tumors
• Localized and operable disease confirmed (stage I-III),
• No prior therapy for localized disease ,
• Age ≥18 years,
• Performance status (PS) 0-2,
• Haematological status: neutrophils (ANC) > 2.0x109/L; platelets >100x109/L; haemoglobin ≥9g/dL,
• Adequate renal function: serum creatinine level <150µM and creatinine clearance test > 30mL/min,
• Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (Upper Limit of Normal)
• Total bilirubin ≤1.5 x ULN,
• Albumin ≥25g/L
• Baseline evaluations performed before inclusion: clinical and blood evaluations no more than 2 weeks (14 days) prior to inclusion, tumor assessment (CT-scan, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to inclusion,
• Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (β HCG) within 72 hours days prior to starting nab-paclitaxel neo-adjuvant and adjuvant treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment,
• Registration in a national health care system (CMU included for France).

Exclusion Criteria:

• Metastatic disease (stage IV)
• Non operable primary tumor
• Patient using warfarin,
• Uncontrolled hypercalcemia (corrected serum calcium > 2.55 mmol/l),
• Pre-existing permanent neuropathy (NCI grade ≥2),
• Known dihydropyrimidine dehydrogenase (DPD) deficiency,
• Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
• Treatment with any other investigational medicinal product within 28 days prior to study entry,
• Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months),
• Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C.
• Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
• Patients with known allergy to any excipient of study drugs,
• Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine and concomitant administration of prophylactic phenytoin
• Patient with any medical or psychological condition, deemed by the investigator to likely interfere with patient's ability to sign informed consent or cooperate and participate in the study, including tutelage or guardianship.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: nab-paclitaxel + FOLFOX; nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)	Drug: nab-paclitaxel; nab-paclitaxel : 150 mg/m2 D1 every 2 weeks; Other Names: ABRAXANE; Drug: FOLFOX; Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Complete pathological response rate	after three months of neoadjuvant chemotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease Free Survival (DFS)		time from the date of inclusion up to the date of disease progression or death whichever occurs last up to 7 years
Overall Survival (OS)		time interval form the inclusion to the date of the death from any cause up to 7 years
Health related to Quality of Life (QoL)		up to 8 months
Safety profile of the combination of nab-paclitaxel + FOLFOX regimen assessed by adverse events		time from randomisation up to end of study up to 7 years
Assessment of biomarkers when appropriate	such as SPARC, TS, DPD, ERCC1	1 day of biopsie from diagnosis, and tumor from surgery
Assessment of genetic polymorphism involved in tumor-response when appropriate	CYP2A6, TS, DPD, ERCC1, ERCC2	28 days after last study treatment

Collaborators and Investigators

• Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
• Collaborators: Celgene Corporation
• Investigators: Principal Investigator: Christophe LOUVET, Institut Mutualiste Montsouris

Study record dates

Study Major Dates

• Study Start: June 1, 2015
• Primary Completion (Actual): October 1, 2017
• Study Completion (Anticipated): June 1, 2022

Study Registration Dates

• First Submitted: June 12, 2015
• First Submitted That Met QC Criteria: June 26, 2015
• First Posted (Estimate): July 1, 2015

Study Record Updates

• Last Update Posted (Actual): February 27, 2019
• Last Update Submitted That Met QC Criteria: February 26, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Adenocarcinoma; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: FOXAGAST -D14-1